SCHEMBL7724227

SCHEMBL7724227

O=C(NCCCn1cccc1)N(CCO)CCC1CCCCC1

nearest known ligand 0.38

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.36
OPRM1 P35372 3/20 0.35
OPRD1 P41143 3/20 0.35
KMT2A Q03164 2/20 0.34
CYP3A4 P08684 2/20 0.34
HPGD P15428 1/20 0.34
CYP2C19 P33261 1/20 0.34
CASR P41180 1/20 0.33
SIGMAR1 Q99720 1/20 0.33
GAA P10253 1/20 0.32
QPCT Q16769 1/20 0.32
EPHX1 P07099 1/20 0.32
MEN1 O00255 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
TSHR P16473 2/20 0.32
TP53 P04637 1/20 0.31
CYP1A2 P05177 1/20 0.31
CYP2D6 P10635 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27501390 0.93 KMT2A (0.36) ALDH1A1OPRM1OPRD1KMT2ACYP3A4
SCHEMBL7719576 0.85 OPRM1 (0.35) ALDH1A1OPRM1OPRD1KMT2ACYP3A4
SCHEMBL7216051 0.83 ALDH1A1 (0.47) ALDH1A1KMT2ACYP3A4SIGMAR1GAA
SCHEMBL7213837 0.83 ALDH1A1 (0.47) ALDH1A1KMT2ACYP3A4SIGMAR1GAA
SCHEMBL6737845 0.80 SIGMAR1 (0.46) ALDH1A1CASRSIGMAR1EPHX1
SCHEMBL7213812 0.80 ALDH1A1 (0.61) ALDH1A1KMT2ACYP3A4HPGDCYP2C19
SCHEMBL6732080 0.79 MEN1 (0.43) ALDH1A1KMT2ACYP3A4CYP2C19CASR
SCHEMBL7214697 0.79 EPHX1 (0.33) ALDH1A1OPRM1OPRD1KMT2ACASR
SCHEMBL7213907 0.78 CA12 (0.40) ALDH1A1KMT2ASIGMAR1MEN1CYP1A2
SCHEMBL7220238 0.78 CA12 (0.40) ALDH1A1KMT2ASIGMAR1MEN1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6420398-B2 FOR TREATING AUTOIMMUNE DISEASES SUCH AS RHEUMATOID ARTHRITIS; 4-(3-(2-(ACETYLTHIO)ETHYL)-3-(2-CYCLOHEXYLETHYL)-UREIDOMETHYL)-1 -METHYLPYRIDINIUM IODIDE, FOR EXAMPLE; INHIBIT PRODUCTION OF TUMOR NECROSIS FACTOR ALPHA (TNF-A) SANTEN PHARMACEUTICAL CO., LTD. (JP) 2002-07-16 US disclosed
US-20010041725-A1 Novel urea derivatives having nitrogen aromatic heterocycle SANTEN PHARMACEUTICAL CO., LTD. (JP) 2001-11-15 US disclosed
EP-1103543-A1 NOVEL UREA DERIVATIVES BEARING NITROGENOUS AROMATIC HETEROCYCLES SANTEN PHARMACEUTICAL CO., LTD. (JP) 2001-05-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010041725-A1 Novel urea derivatives having nitrogen aromatic heterocycle TNF, UACA, HRH4 ALDH1A1 988/4885OPRM1 1235/4885OPRD1 590/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.